Johnson & Johnson Return on Investment 2012-2026 | JNJ
Current and historical return on investment (ROI) values for Johnson & Johnson (JNJ) over the last 10 years.
| Johnson & Johnson ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2026-03-31 | $24.94B | $89.34B | 27.91% |
| 2025-12-31 | $32.58B | $118.46B | 27.50% |
| 2025-09-30 | $31.50B | $113.75B | 27.69% |
| 2025-06-30 | $27.35B | $109.44B | 24.99% |
| 2025-03-31 | $26.60B | $105.81B | 25.14% |
| 2024-12-31 | $16.69B | $100.47B | 16.61% |
| 2024-09-30 | $17.63B | $98.60B | 17.88% |
| 2024-06-30 | $19.51B | $97.55B | 19.99% |
| 2024-03-31 | $20.06B | $99.34B | 20.20% |
| 2023-12-31 | $15.06B | $102.01B | 14.77% |
| 2023-09-30 | $12.72B | $104.27B | 12.20% |
| 2023-06-30 | $12.68B | $105.50B | 12.02% |
| 2023-03-31 | $12.21B | $104.09B | 11.73% |
| 2022-12-31 | $19.36B | $103.53B | 18.70% |
| 2022-09-30 | $18.11B | $103.61B | 17.48% |
| 2022-06-30 | $16.79B | $103.16B | 16.28% |
| 2022-03-31 | $17.61B | $101.97B | 17.27% |
| 2021-12-31 | $19.18B | $100.10B | 19.16% |
| 2021-09-30 | $19.59B | $98.08B | 19.97% |
| 2021-06-30 | $20.14B | $97.26B | 20.71% |
| 2021-03-31 | $17.42B | $94.30B | 18.47% |
| 2020-12-31 | $16.50B | $91.95B | 17.94% |
| 2020-09-30 | $19.07B | $89.46B | 21.31% |
| 2020-06-30 | $16.31B | $86.46B | 18.87% |
| 2020-03-31 | $19.42B | $86.57B | 22.43% |
| 2019-12-31 | $17.33B | $86.55B | 20.02% |
| 2019-09-30 | $16.23B | $86.92B | 18.68% |
| 2019-06-30 | $19.01B | $89.16B | 21.32% |
| 2019-03-31 | $16.94B | $90.11B | 18.80% |
| 2018-12-31 | $18.00B | $91.73B | 19.62% |
| 2018-09-30 | $17.44B | $92.58B | 18.83% |
| 2018-06-30 | $17.80B | $94.22B | 18.90% |
| 2018-03-31 | $17.58B | $95.97B | 18.32% |
| 2017-12-31 | $17.67B | $97.03B | 18.21% |
| 2017-09-30 | $19.44B | $97.54B | 19.93% |
| 2017-06-30 | $19.93B | $96.45B | 20.66% |
| 2017-03-31 | $20.08B | $95.89B | 20.95% |
| 2016-12-31 | $19.80B | $94.77B | 20.90% |
| 2016-09-30 | $19.24B | $92.55B | 20.78% |
| 2016-06-30 | $18.08B | $89.88B | 20.11% |
| 2016-03-31 | $18.92B | $86.93B | 21.76% |
| 2015-12-31 | $19.20B | $84.42B | 22.74% |
| 2015-09-30 | $18.14B | $84.63B | 21.43% |
| 2015-06-30 | $20.83B | $85.66B | 24.32% |
| 2015-03-31 | $20.71B | $87.20B | 23.76% |
| 2014-12-31 | $20.56B | $88.97B | 23.11% |
| 2014-09-30 | $20.61B | $89.60B | 23.00% |
| 2014-06-30 | $17.47B | $87.05B | 20.06% |
| 2014-03-31 | $16.63B | $84.04B | 19.79% |
| 2013-12-31 | $15.47B | $81.12B | 19.07% |
| 2013-09-30 | $15.82B | $78.35B | 20.19% |
| 2013-06-30 | $15.75B | $77.26B | 20.39% |
| 2013-03-31 | $12.99B | $75.42B | 17.22% |
| 2012-12-31 | $13.78B | $74.46B | 18.50% |
| 2012-09-30 | $10.99B | $72.89B | 15.08% |
| 2012-06-30 | $11.51B | $72.74B | 15.82% |
| 2012-03-31 | $12.90B | $73.70B | 17.50% |
| 2011-12-31 | $12.36B | $72.38B | 17.08% |
| 2011-09-30 | $14.27B | $71.31B | 20.01% |
| 2011-06-30 | $14.38B | $69.29B | 20.75% |
| 2011-03-31 | $15.18B | $65.53B | 23.16% |
| 2010-12-31 | $16.95B | $63.49B | 26.69% |
| 2010-09-30 | $17.32B | $61.76B | 28.05% |
| 2010-06-30 | $17.35B | $59.80B | 29.01% |
| 2010-03-31 | $17.39B | $58.21B | 29.88% |
| 2009-12-31 | $15.76B | $55.93B | 28.17% |
| 2009-09-30 | $16.67B | $53.89B | 30.93% |
| 2009-06-30 | $16.71B | $52.76B | 31.68% |
| 2009-03-31 | $16.83B | $52.95B | 31.77% |
| 2008-12-31 | $16.93B | $53.19B | 31.83% |
| 2008-09-30 | $15.74B | $53.13B | 29.63% |
| 2008-06-30 | $14.72B | $51.65B | 28.50% |
| 2008-03-31 | $14.38B | $49.13B | 29.26% |
| 2007-12-31 | $13.28B | $46.67B | 28.46% |
| 2007-09-30 | $13.66B | $44.40B | 30.76% |
| 2007-06-30 | $14.05B | $43.00B | 32.68% |
| 2007-03-31 | $13.62B | $42.39B | 32.14% |
| 2006-12-31 | $14.59B | $42.44B | 34.38% |
| 2006-09-30 | $14.38B | $42.28B | 34.01% |
| 2006-06-30 | $14.14B | $41.39B | 34.17% |
| 2006-03-31 | $13.80B | $40.08B | 34.44% |
| 2005-12-31 | $13.12B | $38.33B | 34.22% |
| 2005-09-30 | $12.73B | $36.74B | 34.65% |
| 2005-06-30 | $12.59B | $35.62B | 35.34% |
| 2005-03-31 | $12.75B | $34.50B | 36.97% |
| 2004-12-31 | $12.33B | $33.33B | 37.00% |
| 2004-09-30 | $12.59B | $32.19B | 39.10% |
| 2004-06-30 | $12.26B | $30.80B | 39.82% |
| 2004-03-31 | $10.88B | $29.44B | 36.96% |
| 2003-12-31 | $10.31B | $28.09B | 36.70% |
| 2003-09-30 | $9.78B | $26.81B | 36.49% |
| 2003-06-30 | $9.23B | $25.64B | 35.99% |
| 2003-03-31 | $9.60B | $24.74B | 38.80% |
| 2002-12-31 | $9.29B | $24.72B | 37.59% |
| 2002-09-30 | $8.89B | $25.15B | 35.33% |
| 2002-06-30 | $8.60B | $25.59B | 33.62% |
| 2002-03-31 | $8.30B | $25.88B | 32.08% |
| 2001-12-31 | $7.90B | $24.81B | 31.84% |
| 2001-09-30 | $7.60B | $24.09B | 31.56% |
| 2001-06-30 | $7.33B | $22.83B | 32.09% |
| 2001-03-31 | $7.11B | $21.63B | 32.87% |
| 2000-12-31 | $6.79B | $21.12B | 32.14% |
| 2000-09-30 | $6.36B | $19.89B | 31.99% |
| 2000-06-30 | $6.21B | $19.01B | 32.65% |
| 2000-03-31 | $6.06B | $17.90B | 33.84% |
| 1999-12-31 | $5.93B | $16.89B | 35.09% |
| 1999-09-30 | $6.24B | $15.94B | 39.14% |
| 1999-06-30 | $5.95B | $15.36B | 38.76% |
| 1999-03-31 | $5.62B | $14.98B | 37.50% |
| 1998-12-31 | $5.32B | $14.57B | 36.54% |
| 1998-09-30 | $5.12B | $14.22B | 36.01% |
| 1998-06-30 | $4.90B | $13.82B | 35.47% |
| 1998-03-31 | $4.76B | $13.46B | 35.39% |
| 1997-12-31 | $4.62B | $13.10B | 35.30% |
| 1997-09-30 | $8.68B | $12.79B | 67.90% |
| 1997-06-30 | $8.69B | $12.53B | 69.42% |
| 1997-03-31 | $4.44B | $12.36B | 35.91% |
| 1996-12-31 | $4.30B | $12.23B | 35.18% |
| 1996-09-30 | $0.04B | $11.96B | 0.30% |
| 1996-06-30 | $-0.21B | $11.61B | -1.77% |
| 1996-03-31 | $3.73B | $11.20B | 33.26% |
| 1995-12-31 | $3.51B | $10.74B | 32.69% |
| 1995-09-30 | $3.43B | $10.28B | 33.39% |
| 1995-06-30 | $3.25B | $9.59B | 33.86% |
| 1995-03-31 | $3.04B | $8.95B | 34.01% |
| 1994-12-31 | $2.05B | $8.33B | 24.56% |
| 1994-09-30 | $1.94B | $7.76B | 24.95% |
| 1994-06-30 | $1.78B | $7.44B | 23.86% |
| 1994-03-31 | $1.69B | $7.19B | 23.53% |
| 1993-12-31 | $2.39B | $7.02B | 34.13% |
| 1993-09-30 | $2.35B | $6.88B | 34.09% |
| 1993-06-30 | $2.34B | $7.02B | 33.39% |
| 1993-03-31 | $2.32B | $6.98B | 33.32% |
| 1992-12-31 | $2.28B | $6.95B | 32.77% |
| 1992-09-30 | $2.31B | $7.05B | 32.71% |
| 1992-06-30 | $2.24B | $6.85B | 32.73% |
| 1992-03-31 | $2.18B | $6.64B | 32.76% |
| 1991-12-31 | $2.16B | $6.52B | 33.19% |
| 1991-09-30 | $2.08B | $6.34B | 32.73% |
| 1991-06-30 | $2.03B | $6.18B | 32.87% |
| 1991-03-31 | $1.96B | $6.07B | 32.24% |
| 1990-12-31 | $1.99B | $5.86B | 34.02% |
| 1990-09-30 | $1.98B | $5.63B | 35.11% |
| 1990-06-30 | $1.92B | $5.41B | 35.57% |
| 1990-03-31 | $1.85B | $5.18B | 35.61% |
| 1989-12-31 | $1.66B | $5.02B | 33.12% |
| 1989-09-30 | $1.56B | $4.85B | 32.23% |
| 1989-06-30 | $1.49B | $4.62B | 32.17% |
| 1989-03-31 | $1.46B | $4.50B | 32.36% |
| 1988-12-31 | $1.40B | $4.40B | 31.90% |
| 1988-09-30 | $1.30B | $4.29B | 30.31% |
| 1988-06-30 | $1.30B | $4.25B | 30.65% |
| 1988-03-31 | $1.30B | $4.02B | 32.37% |
| 1987-12-31 | $1.21B | $3.74B | 32.37% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |